Clinical Trial Update: PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of PEP-DC and OC-DC vaccines for ovarian cancer has been withdrawn. The trial was listed as Withdrawn in ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Carcinoma
• Ovarian Cancer

Drugs mentioned

• OC-DC vaccine (OC-DC)
• PEP-DC vaccine (PEP-DC)

Snippet

Sponsor: Centre Hospitalier Universitaire Vaudois | Conditions: Ovarian Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN